Eton Pharmaceuticals, INC 8-K filings

Eton Pharmaceuticals receives a new U.S. patent for its ET-600 product, a proprietary desmopressin oral solution, providing patent protection through 2044.

Eton Pharmaceuticals reports that the FDA has extended the PDUFA goal date for ET-400 to May 28, 2025, due to the need for additional review time.

Eton Pharmaceuticals has acquired Galzin, an FDA-approved treatment for Wilson Disease, from Teva Pharmaceuticals, further solidifying its commitment to rare disease therapies.

Eton Pharmaceuticals has finalized the acquisition of Increlex, a biologic treatment for severe primary insulin-like growth factor 1 deficiency, from Ipsen S.A., expanding its rare disease portfolio.

Eton Pharmaceuticals reports successful clinical trial results for PKU GOLIKE, demonstrating improved metabolic control in PKU patients during fasting periods.

Eton Pharmaceuticals has entered into a securities purchase agreement to sell 583,334 shares of common stock at $12.00 per share, raising approximately $7 million for potential acquisitions.

Eton Pharmaceuticals has appointed Ipek Erdogan-Trinkaus as its new Chief Commercial Officer, effective immediately.

Eton Pharmaceuticals has secured the U.S. rights to Amglidia, a European-approved treatment for neonatal diabetes, with plans to file a New Drug Application (NDA) in 2026.

Eton Pharmaceuticals reports its first ever positive GAAP net income quarter, driven by a 40% year-over-year increase in product sales and a 15th consecutive quarter of sequential growth.

Eton Pharmaceuticals has been granted a second patent for its ET-400 liquid hydrocortisone formulation, further strengthening its intellectual property protection.

Eton Pharmaceuticals has agreed to acquire Increlex, a treatment for severe primary insulin-like growth factor 1 deficiency, from Ipsen for $22.5 million plus additional payments and inventory purchases.

Eton Pharmaceuticals announced a 40% year-over-year increase in product sales and royalty revenue for the second quarter of 2024, alongside significant pipeline advancements.

Eton Pharmaceuticals will hold advisory Say-on-Pay votes every three years, following a shareholder vote favoring annual votes.

Eton Pharmaceuticals announced that the FDA has accepted its New Drug Application for ET-400, a proprietary hydrocortisone oral solution, with a target action date set for February 28, 2025.

Eton Pharmaceuticals has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Crowe LLP, effective June 14, 2024, following KMJ's resignation due to its partners and staff joining Crowe.

Eton Pharmaceuticals held its 2024 Annual Meeting, where stockholders elected directors, approved executive compensation on an advisory basis, and ratified the appointment of its independent auditor.

Eton Pharmaceuticals reported a 50% year-over-year revenue increase in the first quarter of 2024, fueled by strong sales of ALKINDI SPRINKLE and Carglumic Acid, and strategic acquisitions.

Eton Pharmaceuticals has submitted a New Drug Application to the FDA for its proprietary hydrocortisone oral solution, ET-400, with potential approval anticipated in Q1 2025.

Eton Pharmaceuticals' planned $13.1 million capital raise and $21.9 million credit facility expansion were canceled after the company was not the winning bidder in an auction for certain assets of Eiger BioPharmaceuticals.

Eton Pharmaceuticals has acquired the U.S. rights to PKU GOLIKE, a medical formula for phenylketonuria, from Relief Therapeutics for $2.2 million upfront and potential milestone payments.

Eton Pharmaceuticals announced a 109% increase in Q4 revenue compared to the previous year, marking the twelfth consecutive quarter of sequential product sales growth, alongside positive developments in their drug pipeline.

Eton Pharmaceuticals has been granted a U.S. patent for its proprietary oral liquid hydrocortisone formulation, ET-400, with an expiration date in 2043.

Eton Pharmaceuticals has announced the commercial availability of Nitisinone Capsules, a treatment for hereditary tyrosinemia type 1 (HT-1), with a patient support program offering $0 co-pays for eligible patients.